Palbociclib Intermediate CAS 1016636-76-2 Purity >99.0% (HPLC) Factory

Short Description:

Chemical Name: 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one

CAS: 1016636-76-2

Purity: >99.0% (HPLC)

Appearance: White to Light Yellow Powder

Intermediate of Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Chemical Name	6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one
Synonyms	Palbociclib-Pb3
CAS Number	1016636-76-2
CAT Number	RF-PI1849
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H13BrClN3O
Molecular Weight	342.63
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Light Yellow Powder
Purity / Analysis Method	>99.0% (HPLC)
Related Substances	<1.00%
Loss on Drying	<0.50%
Water (K.F)	<0.50%
Test Standard	Enterprise Standard
Usage	Intermediate of Palbociclib (CAS: 571190-30-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one (CAS: 1016636-76-2) is an intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. On February 3, 2015, the US FDA approved Pfizer's Palbociclib (trade name: Ibrance) for the treatment of advanced/metastatic breast cancer in postmenopausal women. Palbociclib is the first CDK4/6 inhibitor to receive FDA approval.